Exciting New Enterprise for Trial Informatics and Cytel

TI and Cytel look to facilitate a modernized, data driven IDMC with their recent partnership.

Joseph-Femi McKenzie

With the continued rise in the number of new pharmaceutical trials, the demand for accurate, patient-centered IDMC has increased. In recognition of this trend and the MFDS (formerly KFDA) guidelines regarding clinical trial safety and validity, Cytel and TI have formed a partnership to provide more effective IDMC services to sponsors and collectively manage domestic marketing for clinical trials and customer service.

This partnership sees Cytel, one of the world's largest statistical software and leading biometrics providers, further strengthen their relationships in the Asian market by combining their 20 years of DMC experience with Trial-Informatics (TI) and their innovative, CNR-backed, digital management system; OncoTrial Board.

This online platform coordinates and analyzes scattered data, such as medical imaging and digital pathology data, allowing it to be evaluated swiftly and accurately. Entirely cloud-based, OTB affords easy collaboration between multidisciplinary experts; anytime, anywhere, and on any device.

Despite only being established by Dr. Kim in 2021, TI has already been recognized for its creative use of technology and productivity by TIPS Korea and has received investment from field leaders such as CNR.

"With the IDMC from Cytel, we will ensure efficacy and safety monitoring by using our own OTB (OncoTrial Board) solution for the development of the biopharmaceutical and IT industries." - Kyung-Won Kim, CEO of Trial-Informatics.

"As a leader in the DMC field, I am looking forward to Cytel supporting our Korean customers, from the collaborative partnership with TI" - JingPing Yeo, Vice President and Head of APAC, Cytel.

With the goal of increasing the number of internationally sponsored trials, in addition to developing domestic trials, this new relationship and mutual cooperation is expected to benefit both parties greatly.

Helen Kim, General Manager of C&R Healthcare Global, expressed her excitement at this partnership and the opportunities it will present pharmaceutical companies to receive MFDS (KFDA) approval.

About Cytel

Cytel is the largest provider of statistical software and advanced analytics for clinical trial design and execution. For over thirty years, Cytel's scientific rigor and operational excellence have enabled biotech and pharmaceutical companies to navigate uncertainty, prove value and make confident, evidence-based decisions. Its experts deliver industry-leading software, data-driven analytics, real-world evidence and strategic consulting. Headquartered in Waltham, Massachusetts, Cytel has more than 1,500 employees across North America, Europe and Asia. For more information about Cytel, please visit us at www.cytel.com.